Belgian Asit Biotech S.A. (formerly Biotech Tools) has announced that its grass pollen allergic rhinitis immunotherapy gp-ASIT+ did reach the primary efficacy endpoint in a Phase III trial but needs confirmation through an additional Phase III study. Market access is receding into the distance.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-06-19 08:38:322017-06-19 08:38:32Delay in MAA for Asit Biotech’s BTT009
After today’s completion of the acquisition of Actelion Ltd by J&J for US$30bn in cash, equivalent to US$280 per share, through the US company’s Swiss subsidiary, Janssen Holding GmbH, Actelion will become part of Janssen Pharmaceuticals.
Boehringer Ingelheim has presented detailed pivotal double-blinded Phase III data, which prove comparability of its biosimilar candidate BI695501 to Humira in patients with moderate to severe Rheumatoid Arthritis.
Novartis and Alphabet/Google asset Verily Life Sciences LLC has co-invested into the late stage fund designed to finance programmes with up to €25m post clinical proof of concept.
Germany’s Constitutional Court has stopped the government from ratifying the EU’s Unitary Patent Package. At the time of the announcement, The German Bundestag and Council of Federal states had already adopted and signed the legislation.
Contract development and manufacturing organisation Recipharm has appointed Shabbir Mostafa as Director, Business Management UK & Ireland. He will be responsible for supporting customers in the UK and Ireland and driving sales of Recipharm’s manufacturing services.
Orphan diseases diagnostics specialist Centogene AG said it will use the funds for biomarker and CDx development based on its proprietary CentoMD mutation database.
https://european-biotechnology.com/wp-content/uploads/2024/04/Centogene.jpg333500Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-06-13 10:09:112017-06-13 10:09:11Centogene raises a €25m in Series A financing
French vet-med maker Virbac has named Frédéric Jodogne as Corporate Industrial Operations director in early April. He is in charge of implementing, organizing and leading supply chain and industrial strategies of the Group.
Delay in MAA for Asit Biotech’s BTT009
Latest NewsBelgian Asit Biotech S.A. (formerly Biotech Tools) has announced that its grass pollen allergic rhinitis immunotherapy gp-ASIT+ did reach the primary efficacy endpoint in a Phase III trial but needs confirmation through an additional Phase III study. Market access is receding into the distance.
J&J completes acquisition of Actelion
Latest NewsAfter today’s completion of the acquisition of Actelion Ltd by J&J for US$30bn in cash, equivalent to US$280 per share, through the US company’s Swiss subsidiary, Janssen Holding GmbH, Actelion will become part of Janssen Pharmaceuticals.
Boehringer Ingelheim’s Humira biosimilar meets endpoint
Latest NewsBoehringer Ingelheim has presented detailed pivotal double-blinded Phase III data, which prove comparability of its biosimilar candidate BI695501 to Humira in patients with moderate to severe Rheumatoid Arthritis.
Medicxi launches €267m fund
Latest NewsNovartis and Alphabet/Google asset Verily Life Sciences LLC has co-invested into the late stage fund designed to finance programmes with up to €25m post clinical proof of concept.
Germany is blocking EU Unitary Patent Court
Latest NewsGermany’s Constitutional Court has stopped the government from ratifying the EU’s Unitary Patent Package. At the time of the announcement, The German Bundestag and Council of Federal states had already adopted and signed the legislation.
Recipharm: Strategic appointment
AppointmentsAbivax Ebola antiviral gets financing
Latest NewsFrench virology company Abivac will receive €390,000 for the development of a polyclonal antibody cocktail to fight Ebola.
LowCross-Buffer
ProductsAntibody and sample diluent for minimizing nonspecific binding, cross-reactivities and matrix effects in immunoassays.
Centogene raises a €25m in Series A financing
Latest NewsOrphan diseases diagnostics specialist Centogene AG said it will use the funds for biomarker and CDx development based on its proprietary CentoMD mutation database.
Virbac: Managing global operations
Appointments